Core Insights - NovaBridge Biosciences and its subsidiary Visara, Inc. announced positive topline results from the Phase 2a study of VIS-101, a dual VEGF-A X ANG-2 inhibitor for retinal vascular diseases, showing rapid and durable treatment responses in wet AMD [1][2][4] Group 1: Study Results - VIS-101 demonstrated rapid and robust efficacy with mean improvements in Best Corrected Visual Acuity (BCVA) of over 10 ETDRS letters and median central subfield thickness (CST) reductions of 100-150 mm [4][5] - Nearly half of treatment-naïve patients remained retreatment-free for more than six months after three loading doses, indicating potentially best-in-class durability [2][3][5] - The study enrolled 38 patients aged 50-80 years with wet AMD, randomized into 6 mg (n=25) and 3 mg (n=13) dosing groups, with baseline characteristics being similar [7][11] Group 2: Safety Profile - VIS-101 exhibited a favorable safety profile with no dose-limiting toxicity; treatment-related adverse events were 0% in the 3 mg group and 8% in the 6 mg group [9][4] - The data supports the potential of VIS-101 to provide significant benefits to patients with wet AMD and other retinal vascular diseases [3][6] Group 3: Future Development Plans - A Phase 2b dose-determining study is expected to begin in the second half of 2026, followed by a global Phase 3 program anticipated to start in 2027 [4][20] - The positive data from the Phase 2a study is seen as an important milestone for Visara and NovaBridge, enhancing the visibility of their value-creation potential [6][20]